| Literature DB >> 31752130 |
Sultan Akhtar1, Suriya Rehman2, Munirah A Almessiere1,3, Firdos Alam Khan4, Yassine Slimani1, Abdulhadi Baykal5.
Abstract
Manganese metallic nanoparticles are attractive materials for various biological and medical applications. In the present study, we synthesized unique Mn0.5Zn0.5SmxEuxFe1.8-2xO4 (0.01 ≤ x ≤ 0.05) nanoparticles (NPs) by using the hydrothermal approach. The structure and surface morphology of the products were determined by X-ray powder diffraction (XRD), transmission electron and scanning electron microcopies (TEM and SEM), along with energy dispersive X-ray spectroscopy (EDX). We evaluated the impact of Mn0.5Zn0.5SmxEuxFe1.8-2xO4 NPs on both human embryonic stem cells (HEK-293) (normal cells) and human colon carcinoma cells (HCT-116) (cancerous cells). We found that post-48 h of treatment of all products showed a significant decline in the cancer cell population as revealed by microscopically and the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium (MTT) assay. The inhibitory concentration (IC50) values of the products ranged between 0.75 and 2.25 µg/mL. When tested on normal and healthy cells (HEK-293), we found that the treatment of products did not produce any effects on the normal cells, which suggests that all products selectively targeted the cancerous cells. The anti-bacterial properties of the samples were also evaluated by Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) assays, which showed that products also inhibited the bacterial growth.Entities:
Keywords: antibacterial activity; cytotoxicity; hydrothermal synthesis; spinel ferrites
Year: 2019 PMID: 31752130 PMCID: PMC6915425 DOI: 10.3390/nano9111635
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1XRD powder patterns of Mn0.5Zn0.5EuxSmxFe1.5−2xO4 (0.01 ≤ x ≤ 0.05) NPs.
Figure 2SEM of Mn0.5Zn0.5EuxSmxFe1.5−2xO4 for x = 0.01, 0.03, and 0.05 and EDX x = 0.03 NPs.
Figure 3TEM of Mn0.5Zn0.5EuxSmxFe1.5−2xO4 (x = 0.03 and 0.05) NPs.
Effect of Mn0.5Zn0.5SmEuFe1.8−2xO4 (0.01 ≤ x ≤ 0.05) NPs on cancerous cells human colon carcinoma cells (HCT-116) and normal cells human embryonic kidney cells (HEK-293).
| x | IC50 (HCT-116) (µg/mL) | IC50 (HEK-293) |
|---|---|---|
| 0.01 | 0.75 µg/mL | No inhibition |
| 0.02 | 0.85 µg/mL | No inhibition |
| 0.03 | 2.25 µg/mL | No inhibition |
| 0.04 | 0.88 µg/mL | No inhibition |
| 0.05 | 0.79 µg/mL | No inhibition |
Note: IC50 Value [µg/mL] = Inhibitory concentration (IC).
Figure 4Cancer cells stained with 4′,6-diamidino-2-phenylindole (DAPI). HCT-116 cells treated with Mn0.5Zn0.5SmxEuxFe1.8−2xO4 (0.01 ≤ x ≤ 0.05) NPs for 48 h. (A) is control without treatment, (B) treated with Mn0.5Zn0.5SmxEuxFe1.8−2xO4 NPs for x = 0.01 concentration (2.35 µg/mL), and (C) treated with Mn0.5Zn0.5SmxEuxFe1.8−2xO4 NPs for x = 0.05 concentration (2.33 µg/mL). Arrows in B and C indicate the loss of nuclear staining. 200× magnifications.
Figure 5MIC/MBC of Mn0.5Zn0.5SmxEuxFe1.8−2xO4 (0.01 ≤ x ≤ 0.05) against (A) E. coli (B) S. aureus.
Figure 6SEM micrographs of Mn0.5Zn0.5SmxEuxFe1.8−2xO4 (0.01 ≤ x ≤ 0.05) NPs treated (I) E. coli, (II) S. aureus. (a) untreated cells (control), (b) x = 0.01, (c) 0.02, (d) 0.03, (e) 0.04, and (f) 0.05.